Inventor
Jens-Peter VOLKMER
Inventor
US
Overview
Patents· 18 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07KPeptides27%
Y02ATechnologies for adaptation to climate change8%
C12NMicroorganisms or enzymes5%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
PatentTitleYear
12,318,448Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells202512,274,746Dosing parameters for CD47 targeting therapies to hematologic malignancies202512,258,399Methods for achieving therapeutically effective doses of anti-CD47 agents202512,258,403Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody202512,194,093Dosing parameters for CD47 targeting therapies to hematologic malignancies202512,037,402Treatment of cancer with dual targeting of CD47 and EGFR202411,891,450Anti-CD47 agent-based treatment of CD20-positive cancer202411,802,153Anti-CD47 agent-based ovarian cancer therapy202311,766,454Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells202311,753,480Anti-SIRP-alpha antibodies and related methods202311,718,675Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy202311,718,670Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer202311,603,404Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody202311,518,806Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody202211,472,878Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer202211,154,600Use of anti-CD47 agents to enhance immunization202111,141,480Dosing parameters for CD47 targeting therapies to hematologic malignancies202111,136,391Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2025Patents assigned to UNIV LELAND STANFORD JUNIOR (15)· patent assignee history
2021–2024Patents assigned to FORTY SEVEN INC (5)· patent assignee history
2021–2025Based in US· patent location history
2025Patents assigned to FORTY SEVEN LLC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV LELAND STANFORD JUNIOR | 15 | 2021–2025 |
| FORTY SEVEN INC | 5 | 2021–2024 |
| FORTY SEVEN LLC | 2 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 18 | 2021–2025 |